Product image of Igantet (Human Tetanus Immunoglobulin) supplied by GNH India

Igantet

Active Ingredient:
Human Tetanus Immunoglobulin
Origin:
EU

Igantet (Human Tetanus Immunoglobulin)

Human Tetanus Immunoglobulin, the active ingredient in Igantet, is a immunoglobulin (tetanus immune globulin) presented as an injection for intramuscular use. It provides passive immunity for prevention and treatment of tetanus in individuals with insufficient immunization or active disease.

GNH India supplies Igantet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Instituto Grifols, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Igantet (Human Tetanus Immunoglobulin) belongs to the tetanus immune globulin class and provides passive protection against tetanus toxin.
  • Prevention of tetanus: Provides immediate passive immunity for individuals lacking adequate tetanus vaccination.
  • Treatment of tetanus: Supplies neutralizing antibodies to reduce toxin activity in patients with clinical tetanus.
  • Wound management prophylaxis: Administered after high‑risk injuries when vaccination status is uncertain to prevent tetanus infection.

How It Works

  • Human Tetanus Immunoglobulin contains high‑titer anti‑tetanus toxin antibodies that bind circulating tetanospasmin, neutralizing its ability to enter peripheral nerves and block neurotransmitter release, thereby preventing the neurotoxic effects of tetanus.

Side Effects

Igantet may cause adverse reactions related to its immunoglobulin content and the injection process.

Common Side Effects

  • Injection site pain: mild discomfort at the site of intramuscular administration.
  • Redness or swelling: localized erythema or edema around the injection area.
  • Fever: transient low‑grade temperature elevation.
  • Headache: mild to moderate headache occurring shortly after dosing.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction that may include difficulty breathing, hypotension, or rash.
  • Serum sickness: immune complex–mediated reaction presenting with fever, rash, arthralgia.
  • Urticaria: widespread hives indicating hypersensitivity.
  • Hemolysis: rare destruction of red blood cells leading to anemia.

Precautions & Warnings

  • Before using Igantet, consider the following precautions to ensure safe administration.
  • Assess immunization history: Verify the patient’s tetanus vaccination status and need for passive immunization.
  • Known hypersensitivity: Do not administer to individuals with documented allergy to human immunoglobulins or any product component.
  • IgA deficiency: Use with caution in patients with selective IgA deficiency due to risk of anaphylactic reactions.
  • Concurrent vaccines: Delay active tetanus vaccination for at least 4 weeks after Igantet to avoid interference with antibody response.
  • Pregnancy and lactation: Weigh potential benefits against unknown risks; consult obstetric guidance.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Igantet can interact with other agents that affect immune response or vaccine efficacy.

Major Interactions (Avoid)

  • Simultaneous tetanus toxoid vaccine: may reduce the immunogenicity of the active vaccine.
  • IgA‑deficient plasma products: increased risk of severe allergic reactions.

Moderate Interactions (Monitor Closely)

  • Live vaccines administered within 4 weeks: possible diminished effectiveness; monitor immune status.
  • Immunosuppressive therapy: may alter the duration of passive protection; assess antibody levels if needed.
  • Anticoagulants: intramuscular injection may increase bleeding risk; apply pressure after administration.

Frequently Asked Questions

Igantet is a human tetanus immunoglobulin preparation used to provide immediate passive immunity in people who have not been adequately vaccinated against tetanus or who are already developing tetanus. It is also administered as prophylaxis after high‑risk injuries when the tetanus vaccination status is uncertain.

The product contains purified antibodies that specifically bind tetanus toxin (tetanospasmin). By neutralizing the toxin in the bloodstream, the antibodies prevent it from reaching nerve endings and blocking neurotransmitter release, thereby stopping the progression of tetanus symptoms.

The exact dose of Igantet is determined by the prescribing clinician based on factors such as the patient’s age, weight, severity of exposure, and current immunization record. Dosing guidelines are provided in the product’s prescribing information and must be followed by a qualified health professional.

Safety data for Igantet in pregnancy and lactation are limited. The decision to use the product in pregnant or nursing women should be based on a careful assessment of the potential benefits versus unknown risks, and it should be made in consultation with obstetric and infectious‑disease specialists.

To order Igantet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

The primary alternative to Igantet is active tetanus vaccination (tetanus toxoid). While the vaccine stimulates the body to produce its own antibodies over weeks, Igantet delivers ready‑made antibodies that act immediately. Igantet is therefore preferred for rapid protection in emergencies, whereas the vaccine is used for long‑term immunity.

Igantet must be stored at 2 °C to 8 °C (refrigerated). It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain is essential to preserve antibody stability and efficacy.

Igantet is given by a single intramuscular injection, usually into the deltoid or gluteal muscle. The administration technique follows standard aseptic injection practices, and the injection site should be monitored for local reactions after dosing.

The most serious risks include severe allergic reactions such as anaphylaxis, serum sickness, and rare hemolytic events. Prompt recognition of symptoms like difficulty breathing, hypotension, widespread rash, or sudden drop in hemoglobin is critical, and emergency medical treatment should be initiated immediately.

Igantet should not be given to individuals with a known hypersensitivity to human immunoglobulins or any excipients in the formulation. Patients with a history of severe allergic reactions to blood‑derived products should avoid the product unless the benefits clearly outweigh the risks and appropriate precautions are taken.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Tetanus Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT